NO984197D0 - Fremgangsmåte for behandling av autisme - Google Patents

Fremgangsmåte for behandling av autisme

Info

Publication number
NO984197D0
NO984197D0 NO984197A NO984197A NO984197D0 NO 984197 D0 NO984197 D0 NO 984197D0 NO 984197 A NO984197 A NO 984197A NO 984197 A NO984197 A NO 984197A NO 984197 D0 NO984197 D0 NO 984197D0
Authority
NO
Norway
Prior art keywords
procedures
treating autism
treating
autism
olanzapine
Prior art date
Application number
NO984197A
Other languages
English (en)
Other versions
NO984197L (no
Inventor
Jr Charles M Beasley
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO984197D0 publication Critical patent/NO984197D0/no
Publication of NO984197L publication Critical patent/NO984197L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
NO984197A 1996-03-11 1998-09-11 FremgangsmÕte for behandling av autisme NO984197L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11
PCT/US1996/019576 WO1997033585A1 (en) 1996-03-11 1996-12-04 Method for treating autism

Publications (2)

Publication Number Publication Date
NO984197D0 true NO984197D0 (no) 1998-09-11
NO984197L NO984197L (no) 1998-11-03

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984197A NO984197L (no) 1996-03-11 1998-09-11 FremgangsmÕte for behandling av autisme

Country Status (19)

Country Link
EP (1) EP0946179B1 (no)
JP (1) JP2000506860A (no)
KR (1) KR19990087715A (no)
CN (1) CN1213970A (no)
AT (1) ATE249832T1 (no)
AU (1) AU709181B2 (no)
BR (1) BR9612552A (no)
CA (1) CA2248741A1 (no)
CZ (1) CZ290498A3 (no)
DE (1) DE69630055T2 (no)
EA (1) EA000768B1 (no)
ES (1) ES2206614T3 (no)
HU (1) HUP9903688A3 (no)
IL (1) IL126161A0 (no)
NO (1) NO984197L (no)
NZ (1) NZ324615A (no)
PL (1) PL328948A1 (no)
TR (1) TR199801798T2 (no)
WO (1) WO1997033585A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351719A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
CA2352611A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
ATE286398T1 (de) 1998-11-23 2005-01-15 Sepracor Inc Desmethylolanzapine enthaltende zusammensetzungen und verfahren
CA2879113C (en) 2012-07-22 2021-11-16 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
CA2926645C (en) 2013-10-14 2022-10-25 Indiana University Research And Technology Corporation Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
EP0946179A1 (en) 1999-10-06
ATE249832T1 (de) 2003-10-15
KR19990087715A (ko) 1999-12-27
HUP9903688A2 (hu) 2000-03-28
PL328948A1 (en) 1999-03-01
TR199801798T2 (xx) 1998-12-21
WO1997033585A1 (en) 1997-09-18
AU1150197A (en) 1997-10-01
HUP9903688A3 (en) 2001-12-28
CA2248741A1 (en) 1997-09-18
NO984197L (no) 1998-11-03
BR9612552A (pt) 1999-07-20
EP0946179B1 (en) 2003-09-17
AU709181B2 (en) 1999-08-26
EP0946179A4 (en) 2000-04-19
NZ324615A (en) 2000-08-25
DE69630055D1 (de) 2003-10-23
CN1213970A (zh) 1999-04-14
ES2206614T3 (es) 2004-05-16
JP2000506860A (ja) 2000-06-06
EA199800821A1 (ru) 1999-02-25
IL126161A0 (en) 1999-05-09
CZ290498A3 (cs) 1999-10-13
EA000768B1 (ru) 2000-04-24
DE69630055T2 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
PT880350E (pt) Tratamento de esclerose multipla
ATE181422T1 (de) Verfahren zur diagnose von praeklampsie
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
NO984197D0 (no) Fremgangsmåte for behandling av autisme
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
EA199800818A1 (ru) Способ лечения бессонницы
UA31502A (uk) Спосіб визначення індивідуальної чутливості онкохворого до спеціального протипухлинного лікування
NO984964L (no) Anvendelse av fosfonsyreestere for behandling av funksjonelle forstyrrelser i hjernen og ved depresjon
BA95039A (bs) Set za prevenciju i terapiju bolne menstruacije
UA7951A (uk) Спосіб сочетаної вакуум-лазерної терапії
UA27148C2 (uk) Спосіб лікуваhhя гострого пієлоhефриту
DE29504377U1 (de) Autoinjector zur Behandlung der akuten respiratorischen Insuffizienz

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application